Global Liquid Biopsy Market Report- Market Size, Share, Growth, Company profiling. Market Analysis by Product, Cancer Type, Technology, End Users and Geography With COVID-19 impact | Forecast Period 2017-2030

Global Liquid Biopsy Market Outlook (2017-2030)

A biopsy is a test conducted by surgeon, cardiologist or radiologist which involves withdrawal of certain cell or tissues to examine the existence of some disease in the body. It is observed under microscope by surgeon or pathologist. The extracted cell or tissues are examined to know that the particular cell is cancerous or not, and if they are then what type of cancer is present.

Geographically, North America is the largest region holding around 33.5% market share in 2016. Western Europe is the second largest region accounting for over 26.2% market share in 2016 following North America. This is due to increase adoption of hybrid imaging technology in the entire region.

One of the major factors that propel the growth of liquid biopsy market is through a single extraction of cell from the body, patient disease can be easily known. However, expensive treatment of such procedures can hamper the global liquid biopsy market from growth.

Global Liquid Biopsy Market Segmentation 

On the basis of product:

1. Reagents
2. Instruments

On the basis of cancer type:

1. Lung cancer
2. Breast cancer
3. Liver cancer
4. Prostate cancer
5. Others

On the basis of technology:

1. Circulating tumor cells
2. Circulating endothelial cells
3. Cell free circulating DNA

On the basis of end user:

1. Reference laboratories
2.  Hospital/physician laboratories
3. Academic and research centers

On the basis of region:

1. North America(U.S, Canada, Mexico) Liquid Biopsy Market
2. Europe(Germany, France, UK, Italy, Spain, Rest of Europe) Liquid Biopsy Market
3. Asia-Pacific( Japan, China, Australia, India, South Korea, Taiwan, Rest of Asia-Pacific) Liquid Biopsy Market
4. Middle East ( Brazil, Turkey, Saudi Arab, South Africa, Rest of LAMEA) Liquid Biopsy Market
5. Latin America (Brazil, Mexico, Argentina & Rest of Latin America) Liquid Biopsy Market {Market Share (%), Market Size (USD Billion)}

Global Liquid Biopsy Market size and forecast

Global liquid biopsy market is an emerging market globally and will show an exponential growth in six to seven years. Global Liquid Biopsy Market was valued at USD 635.25 million in 2016, and is estimated to  registering a CAGR of 28.9% from 2017 to 2030.

On the basis of technology the circulating tumor cells segment is accounted for the largest share of the global liquid biopsy market in 2016, followed by the circulating tumor DNA segment.

Geographically, North America is the largest region in global liquid biopsy market which is accounted for 33% market share in 2016. 

Europe is the second region followed by North America in global liquid biopsy market. Europe is the second largest region crossing the value of USD 685.02 million by 2024 followed by APAC

Growth drivers and restraints

A number of constituents such as soaring circumstances of cancer, increasing awareness about biopsy to population and rising government initiatives to create awareness propel the growth of liquid biopsy market and tends the market towards growth.

However, unclear regulatory reimbursement scenario, expensive medical procedure and cost intensive research process may hamper the global liquid biopsy market from growing.

COVID-19 impact on "Global Liquid Biopsy Market "    

Impact of COVID-19 Outbreak on “Global Liquid Biopsy Market ”, Manufacturers, Contract Manufacturers Suppliers and Recovery Strategy. A complete detailed chapter of 50-70 pages which includes the data and information focused on impacts of the pandemic on the Global Liquid Biopsy Market . It also showcases the expected recovery schedule and losses in the industry and other various major factors.

Key players:

1. NeoGenomics
   • Synopsis
   • Business Strategy
   • Product Portfolio
   • SWOT Analysis
2. Biocartis
3.  Guardant Health
4. Trovagene
5. Pathway Genomics
6. Biocept inc.
7. QIAGEN
8. Cambridge Epigenetix
9. Inivata
10. Nodexus
11. Genomic Expression
12. LARIAT BIOSCIENCES, INC.
13. GPB SCIENTIFIC, LLC
14. Bert Vogelstein, Johns Hopkins
15. Elypta
16. Cambridge Oncometrix Limited
17. Epigenomics AG
18. Genetron Health Technologies Inc.
19. Stem Sel
20. Vortex Biosciences
21. Cynvenio Biosystems
22. Mursla
23. NetScientific
24. Clearbridge BioMedics Pte Ltd
25. OncoCyte Corporation
26. Circulogene
27. CYTOFIND DIAGNOSTICS BV
28. SIMFO GmbH
29. Liquid Biopsy
30.  Illumina

Opportunities and risk factors:

There are several opportunities which can tend the growth of markets such as surge in prevalence of cancer and rise in awareness about minimally invasive methods among the patient pool

Several risk factors involve in these market are there are several multiple test going on, several experiments takes place that sometimes fails and also there is no surety that the experiment will succeed or not.

Key Questions Answered In This Liquid Biopsy Market Report

• What is the total market size by 2030 and what would be the expected growth rate of the market?
• What is the revenue of liquid biopsy in 2017-18 and what would be the expected demand over the forecast period?
• What are the key market trends?
• What are the factors which are driving this market?
• What are the major barriers to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities for the existing and entry-level players?
• What are the recent developments and business strategy of the key players?